title: Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation?
abstract: OBJECTIVE
  The purpose of this study was to assess the pregnancy-related cardiovascular risk in LQT1 patients.
  
  
  BACKGROUND
  Only 1 study addressed this issue in genotyped patients and reported that the highest risk is for LQT2 patients.
  
  
  METHODS
  This case-control study, performed in a cohort of patients from 22 families affected by LQT1 and all sharing the common KCNQ1-A341V mutation, involved 36 mutation carriers and 24 of their unaffected sisters for a total of 182 pregnancies.
  
  
  RESULTS
  There were 3 (2.6%) cardiac events (2 cardiac arrests) in the 115 LQT1 pregnancies. Because they occurred only among the 27 mothers with previous symptoms, all off-therapy, the risk for symptomatic patients is 11%, but decreases to 0 in symptomatic patients treated with beta-blockers. Carriers and control subjects did not differ for the incidence of miscarriage (10% vs. 15%). Cesarean sections (C-sections), elective or owing to fetal distress, were performed more often in carriers than in non-carriers (27% vs. 14%). Beta-blocker therapy did not influence the prevalence of fetal distress. Among the infants born to carriers, all those with fetal distress were carriers of the A341V mutation (10 of 10, 100%). Among the offspring of the carriers, 48 of 92 (52%) were mutation carriers, and of those, 15% died suddenly at age 14 +/- 6 years.
  
  
  CONCLUSIONS
  Women affected by the common KCNQ1-A341V mutation are at low risk for cardiac events during pregnancy and without excess risk of miscarriage; their infants delivered by C-section because of fetal distress are extremely likely to also be mutation carriers. Beta-blockers remain recommended. These conclusions likely apply to most LQT1 patients.
authors.affiliation: Department of Internal Medicine, University of Stellenbosch, Stellenbosch, South Africa.
authors.forename: Marshall J
authors.initials: MJ
authors.lastname: Heradien
authors.forename: Althea
authors.initials: A
authors.lastname: Goosen
authors.forename: Lia
authors.initials: L
authors.lastname: Crotti
authors.forename: Glenda
authors.initials: G
authors.lastname: Durrheim
authors.forename: Valerie
authors.initials: V
authors.lastname: Corfield
authors.forename: Paul A
authors.initials: PA
authors.lastname: Brink
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Schwartz
mesh_terms: D000022:Abortion, Spontaneous; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000328:Adult; D016022:Case-Control Studies; D002585:Cesarean Section; D005260:Female; D005316:Fetal Distress; D005838:Genotype; D006323:Heart Arrest / Q000209:etiology*; D006801:Humans; D007231:Infant, Newborn; D051657:KCNQ1 Potassium Channel / Q000235:genetics*; D011247:Pregnancy; D011248:Pregnancy Complications / Q000235:genetics*; D011256:Pregnancy Outcome; D012307:Risk Factors; D029597:Romano-Ward Syndrome / Q000150:complications* / Q000188:drug therapy / Q000235:genetics*
chemical_list: D000319:Adrenergic beta-Antagonists; D051657:KCNQ1 Potassium Channel; C496909:KCNQ1 protein, human